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PRÁTICA CLÍNICA
the registration of all biosimilar treated patients in
Reuma.pt for efficacy, safety and immunogenicity
surveillance, following the strategy already ongoing for
originators, and opposes to extrapolation of indications
approved to the originator to completely different di -
seases and/or age groups without adequate pre-clini-
cal, safety or efficacy data.
Keywords: Biosimilar; Infliximab; Position paper; Re-
view; Rheumatoid arthritis; Ankylosing spondylitis;
Switching; Interchangeability; Automatic substitution;
Extrapolation.
IntroductIon
Biotechnological medicines have profoundly changed
the treatment and prognosis of rheumatic diseases1.
However, these therapies represent a significant eco-
nomic burden to healthcare systems worldwide. With
some of these biopharmaceutical products approaching
patent expiration, the opportunity arises for the deve -
lopment of similar versions whose lower cost is expect -
ed not only to improve cost-efficacy ratios, but also to
improve drug access, especially in countries with eco-
nomic restraints2. The biopharmaceutical medicines
currently used in rheumatology are monoclonal an -
tibodies (mAbs) and soluble receptor fusion proteins
(Cepts). They have an inherent complexity and varia -
bility that originates from their production in living
cells, their highly intricate protein structure (with ter-
tiary and quaternary structures) and their post-trans-
lational modifications (such as glycosylation)3. In the
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AbstrAct
Biotechnological drugs have become a fundamental re-
source for the treatment of rheumatic patients. Patent
expiry of some of these drugs created the opportunity
for biopharmaceutical manufacturers to develop
biosimilar drugs intended to be as efficacious as the
originator product but with a lower cost to healthcare
systems. Due to the complex manufacturing process
and highly intricate structure of biologicals, a biosimi-
lar can never be an exact copy of its reference product.
Consequently, regulatory authorities issued strict pre-
clinical and clinical guidelines to ensure safety and
effica cy equivalence and, in September 2013, the
biosimilar of infliximab was the first biosimilar mono-
clonal antibody to be authorized for use in the Euro-
pean Union. The current document is a position state-
ment of the “Sociedade Portuguesa de Reumatologia”
(Portuguese Society of Rheumatology) on the use of
biosimilar drugs in rheumatic diseases. Two systema tic
literature reviews were performed, one concerning cli -
nical trials and the other one concerning international
position papers on biosimilars. The results were pre-
sented and discussed in a national meeting and a final
position document was discussed, written and appro -
ved by Portuguese rheumatologists. Briefly, this posi-
tion statement is contrary to automatic substitution of
the originator by the biosimilar, defends either a diffe -
rent INN or the prescription by brand name, supports
that switching between biosimilars and the originator
molecule should be done after at least 6 months of treat-
ment and based on the attending physician decision
and after adequate patient information, recommends
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context of prescribing any approved biologic, it is im-
portant to understand the challenges faced in biolo gic
manufacturing and the potential clinical implications.
Information that can assist prescribing decisions con-
cerning the utilization of similar biologics includes
clinical trial results, regulatory approvals and product
labels4, 5. Throughout the product life cycle of an
appro ved biologic molecule, a manufacturer may im-
plement process changes to incorporate technological
advances or efficiencies. Regulators evaluate these
changes carefully and use scientific comparability cri-
teria to determine whether there is a potential impact
on the safety or efficacy that underlies its approval.
Most of these manufacturing changes are evaluated
with analytic studies designed to assess the potential
for an unexpected change in the quality of the com-
mercial product6. Information on the changes intro-
duced and the data used to support these changes are
generally not available in the public domain. Occa-
sionally, however, a major manufacturing change will
require that the manufacturer completes a clinical tri-
al to demonstrate that there is no impact on the pro -
duct’s safety or efficacy.
After patent expiry of an originator medicine, bio-
pharmaceuticals can be developed and marketed by
other manufacturers, which must demonstrate simi-
larity to a reference product. Since biosimilars can ne -
ver be exact copies of their reference product, gran -
ting of a market authorization is therefore subject to
strict regulatory approval2-5,7. Biosimilar-manufactur-
ing companies do not have access to the original pro-
cess; hence they have to reverse-engineer it from the
original molecule. It is unlikely that a perfectly identi-
cal molecule can be recreated from the reference pro -
duct, not only due to developmental differences but
also due to molecular micro-heterogeneities common
to all biotechnological drugs. Modifications of the pri-
mary, secondary, tertiary, or quaternary structure of an
approved biologic may impact its potency, purity and
safety that underlie its approval. As a result, meticulous
attention is required to assure the proper function and
integrity of the manufacturing environment for pro-
ducing approved biologics4, 5.
While the evaluation of a new manufacturing pro-
cess for a biosimilar may parallel a manufacturing pro-
cess change for a biologic, there are important dis-
tinctions to consider2,3,7-9. The biosimilar manufactu rer
must develop the manufacturing process in its entire-
ty, from cell line selection to fill and finish. These ac-
tivities are performed without full access to the inno-
vator manufacturer’s product development history.
Due to the potential for differences, a biosimilar manu -
facturer should provide data to ensure that diffe rences
between the biosimilar and the innovator biologic will
not impact the efficacy or safety of its pro duct. Con-
sidering the current limitations of analytical methods,
these data should include comparative clinical testing
with the reference biopharmaceutical to confirm
biosimilarity2-5,7-9. Although the extent of clinical tes -
ting of the similar biological product is likely to be less
than is normally required for an original product (new
biological entity), it is essential that the testing of the
similar biological product be sufficient to ensure that
the product meets acceptable levels of quality, safety
and efficacy to ensure public health10. Generally, a re-
duction in data requirements is possible for non-clini -
cal and/or clinical parts of the development program
by guaranteeing quality of product, which may vary
depending on the characteristics of the already ap-
proved reference product10,11. A major difference for
biosimilar products is that they can be recognized for
indications of reference products without performing
clinical studies for all the clinical indications that refe -
rence products are approved for, supposing the equiva -
lence with reference products by extrapolation of their
indications2, 3, 11.
Therefore, a biosimilar can be defined as a biothera -
peutic product, which is similar but not identical in
terms of quality, safety and efficacy to an already li-
censed reference biotherapeutic product7. They are, by
definition, distinct from generics, whose smaller
chemi cal structure is simple to accurately replicate.
Granting marketing authorizations (MA) for biote -
chnology products falls under the authority of the Eu-
ropean Medicines Agency (EMA). However, once au-
thorized through these channels, individual Member
States must develop processes regarding the prescri -
ption, delivery and use of biological and/or biosimilar
products. These processes vary widely across the EU
Member States1-3,7,8. Europe is ahead of the United Sta -
tes when it comes to biosimilar adoption. The EMA
approved its first biosimilar in 2006. 
The Guidelines on similar biological medicinal
products containing biotechnology-derived proteins
as active substance: Quality (EMEA/CHMP/49348/05)
and Non-clinical & clinical issues (EMEA/CHMP/
BMWP/42832/05) lay down the requirements for a
bio logical medicinal product claiming to be similar to
another one already marketed. Both these guidelines
were adopted by EMA in June 2006. The Committee
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for Medicinal Products for Human Use (CHMP) has
published over half-a-dozen guidelines related to
biosimilar products, including guidelines on specific
classes of biological products such as insulin and so-
matropin, as well as draft guidelines on monoclonal
antibodies and a “concept paper” on low-molecular
weight heparins. Since then, several biosimilar pro -
ducts have come into the EU market and the number
of scientific advices given by the CHMP on the deve -
lopment of biosimilar products has increased signifi-
cantly. Almost all biosimilars licensed in Europe, thus
far, fall into three categories: somatropin, epoetin alpha
and filgrastim. These are all relatively small biologics
and none of them is as large or complex as mAbs. On
the other hand, these approvals have at least demons -
trated proof of concept that biosimilars can be manu-
factured in different expression systems yet still be
“similar.” For example, the biosimilar Valtropin is ex-
pressed in yeast culture, whereas the original Huma -
trope is expressed in E. coli systems. In 2012, EMA is-
sued guidelines for biosimilar mAbs with the manda-
tory non-clinical (in vitro biological activity) and clini -
cal (in vivo pharmacokinetics, pharmacodynamics,
efficacy and safety) studies required for medicine ap-
proval8. The biosimilar of infliximab, a tumour necro-
sis factor (TNF) blocker, was first authorized for use in
the European Union on September 10th, 2013, as
branded names Inflectra and Remsima12,13. 
The key principles of regulating biosimilars have
been the same across different agencies. They all em-
phasize the fact that the development of a biosimilar
involves stepwise, risk based, comparability exercise(s)
starting with comparison of the quality characteristics
of the biosimilar and original biologic. Demonstration
of similarity in terms of quality is a prerequisite for the
reduction of the non-clinical and clinical data set re-
quired for licensing. After each step of the compara-
bility exercise, the decision to proceed further with the
development of the biosimilar should be evaluated. If
relevant differences are found in the quality, non-clini -
cal, or clinical studies, the product will not qualify as
biosimilar and a more extensive non-clinical and clini -
cal data set will likely be required to support its appli-
cation for licensing. EMA is emphasizing the need to
follow the 3 R principles (replacement, reduction and
refinement) and is also considering to potentially re-
vise the existing guidelines. At a minimum, pharma-
cokinetic and pharmacodynamic (PK/PD) studies
would be required to establish sufficient similarity. 
Progress in the characterization and understanding
of biologics now permits demonstration that some
products are highly similar to a reference product.
Physicochemical and functional assays have been used
to characterize changes in manufacturing processes for
some biologics, and then animal or clinical studies are
used to resolve any remaining uncertainties about the
comparability of the products created before and after
such changes and to provide sufficient confidence that
safety and efficacy are not diminished. There may be
strategies that allow a “fingerprint”-like identification
of very similar patterns in two different products. Such
strategies were used in supporting the approval of
highly complex heparin product, enoxaparin, or low-
-molecular weight proteins with complex glycosyla-
tion like erythropoietins. Although additional animal
and clinical studies will generally be needed for pro-
tein biosimilars for the foreseeable future, the scope and
extent of such studies may be reduced further if more
extensive fingerprint-like characterization is used.
With regard to the phase I studies, the general gui -
deline EMEA/CHMP/BMWP/42832/05 and the spe-
cific mAb guideline EMA/CHMP/BMWP/403543/
/2010 recommend the selection of relevant pharma-
codynamic (PD) markers, but such markers are not al-
ways available and/or cannot be shown to reflect effi-
cacy. On the other hand, when relevant surrogate
markers do exist, the current guideline includes the
possibility of using them (e.g. absolute neutrophil
count to assess the effect of granulocyte-colony stimu -
lating factor) as the primary end points in the pivotal
phase III studies. This aspect could be expanded to
further elaborate on the underlying principles, poten-
tially including examples from other therapeutic 
areas. Regarding the immunogenicity data, one-year
follow-up data are requested in the current guideline
(EMA/CHMP/BMWP/ /86289/2010) in case of chro -
nic administration. With regard to the measurement of
antibodies, an optimal sampling schedule should be
considered in order to take into account e.g. the onset
and duration of the antibody formation as shown by
the data of the reference product. 
EMA regulations do not require the applicant to 
obtain comprehensive data on patient benefit. It requi -
res, however, the follow-on biologic applicant to
demonstrate similar efficacy and safety compared to
the reference product. The biosimilar applicant will
have to conduct testing and a clinical trial of some sort,
but for this pathway to have any practical meaning
such trials must be significantly shorter and less com-
prehensive than the original applicant’s. This stand-
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point represents a new paradigm in medicines eva -
luation, where the quality and pre-clinical assessment
represents the largest evaluation performed by EMA.
The pre-clinical assessment is based on scientifically
recognized pharmacokinetic and pharmacodynamic
biomarkers for each clinical indication of the original
drug. The exploratory clinical development program
for assessing patient benefit is substituted by confirma -
tion with clinical studies, where the goal is to show
bioequivalence compared to the approved original
mAb.
Because biosimilars are approved through an abbre -
viated clinical trial program and may not be tested in
all indications of the originator, extrapolation of indi-
cations is an issue of concern. Extrapolation of scien -
tific evidence should be seen as a logical consequence
of the comparability exercise principle, which is based
in physiochemical and biological characterization. Any
uncertainties, such as slight differences of unknown
relevance to clinical performance, should be addressed
via comparative clinical data. The totality of evidence
for each biosimilar applicant should be reviewed as a
whole on a case-by-case basis, with extrapolation
viewed not as an “extra” for the developer of the
biosimi lar, but rather as the applicant’s burden to col-
lect and demonstrate stringent scientific evidence.
The current document has the goal of expressing
the position of the Portuguese Society of Rheumato -
logy (SPR) concerning the use of biosimilars in Portu-
gal, based on the evidence available so far and on the
opi nion of its affiliates. 
methods
A systematic literature review of the clinical trials of
the biosimilars that are positioned to be used in
rheuma tic diseases was performed. A MEDLINE search
up to September 2013 was done using relevant search
terms in order to include all clinical trials assessing the
efficacy and safety of biosimilar candidates to be used
in the field of rheumatology.
A systematic literature review of the International
Position Papers on the use of  biosimilar drugs was also
carried out. We included the position of other medi-
cal, pharmaceutical and scientific organisations con-
cerning the use of biosimilar drugs, particularly those
addres sing less consensual aspects such as inter-
changeability, substitution and extrapolation of data.
Therefore, we developed a systematic literature search
through MEDLINE using relevant search terms
(“biosimilars”[MeSH]), without date or language res -
trictions, for position papers addressing the use of any
biosimilar drug. The search was supplemented with a
hand search through the websites of several interna-
tional societies.
The results of this evidence-based approach were
presented and discussed during a national meeting of
the Portuguese Society of Rheumatology (SPR) that
took place during the 5th and 6th of October 2013.
During the meeting, a first plenary session was dedi-
cated to an open discussion and to the elaboration of
a first draft of a bullet like SPR position on the use of
biolosimilars in the field of rheumatology. A steering
committee made a final proposal of this position,
which was adapted and approved in a second plenary
mee ting that took place in the following day. 
results 
clInIcAl trIAls In bIosImIlAr cAndIdAtes to
be used In rheumAtology: A systemAtIc
lIterAture revIew
Of the 312 articles screened, 6 were selected for detail -
ed review and 2 fulfilled our inclusion criteria. Two 
abs tracts from the EULAR congress were also inclu ded. 
The first trial was the phase I PLANETAS trial14,
which compared CT-P13 and originator infliximab in
patients with active ankylosing spondylitis. The pri-
mary endpoint, pharmacokinetics, and clinical effica-
cy endpoints, including ASAS 20 and ASAS 40 res -
ponses, were highly similar between CT-P13 and in-
fliximab groups. CT-P13 had a safety profile compara-
ble to that of infliximab up to the 30th week.
The second trial was the phase III PLANETRA tri-
al15, which compared CT-P13 and originator infliximab
in patients with rheumatoid arthritis. CT-P13 and origi-
nator infliximab were shown to be equivalent in terms
of ACR 20 response at week 30 in patients with active
rheumatoid arthritis despite methotrexate treatment.
Overall, CT-P13 was well tolerated and the safety pro-
file of CT-P13 was comparable with that of infliximab.
At the 2013 EULAR meeting, the results at 54 weeks
of the PLANETAS and PLANETRA trials were pu -
blished as abstracts. Once again, CT-P13 showed com-
parable efficacy and safety to originator infliximab in
patients with active ankylosing spondylitis and
rheumatoid arthritis with inadequate response to
methotrexate treatment.
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There are seven ongoing biosimilar clinical trials, all
in patients with rheumatoid arthritis: five trials refer to
rituximab, one to etanercept and one to infliximab.
There is still no published data on these trials.
The clinical trials included in this review have
demonstrated a similar efficacy and safety profiles 
between the tested biosimilars and the original drugs,
granting recent approval of CT-P13 by EMA. 
InternAtIonAl PosItIon PAPers on the use
of bIosImIlAr drugs: A systemAtIc 
lIterAture revIew
We identified a total of 166 papers (MEDLINE - 143 re-
sults, hand search – 23 results), of which 137 were ex-
cluded after a title and abstract suitability scrutiny. The
remaining 29 papers were submitted to detailed review
and all were included in our study (Table I).
Approximately half of the position statements were
issued by European organizations, while about one fifth
of the papers were of North American origin and the re-
mainders were of different multinational provenances.
The type of organizations included medical societies/
/colleges, health-related non-profit non-governmental
organizations, governmental departments, pharma-
ceutical associations and pharmaceutical manufactu -
rers. Most (58%) papers were published in the last 2
years and the dates of publication of all included papers
were comprised in the last 8 years (2007 to 2013).
All papers were favourable to the use of biosimilars,
provided the safety, efficacy and quality of the drugs
were assured. Forty-five percent of papers were clear-
ly in opposition to automatic substitution (i.e. the le-
gal authority for a pharmacy filling a prescription to
switch the innovator product to the biosimilar without
physician approval) and all papers indirectly advised
against this practice by restricting interchangeability of
biosimilar drugs to the consent of the attending physi-
cian (62% of papers), as well as of the patient (14% of
papers). The automatic extrapolation of the approval of
biosimilar drugs to other indications different from the
ones specifically tested in trials gathered low consen-
sus (unacceptable for 44.8% of the papers). Another
source of concern was expressed by many position pa-
pers regarding the possibility of biosimilars having the
same International Non-proprietary Name (INN) as the
originator molecule. In such conditions, 41.4% of the
papers defended that prescription should be performed
by brand name. Safety concerns were expressed by
most organisations, particularly regarding immuno-
genicity and other potentially unexpected drug related
adverse events. Table II summarizes the most relevant
position trends found.
the Portuguese socIety of 
rheumAtology PosItIon on the use of
bIosImIlAr drugs In the fIeld of 
rheumAtIc dIseAses
drug selectIon 
– In patients naïve to biotechnological drugs, the
thera peutic choice among the approved biologic
drugs (originators or biosimilars) must be dictated
by an assessment of the individual risk-benefit pro-
file (i.e. taking into consideration patient’s age, co
morbidities, previous infections, concomitant treat-
ments and functional status) and should not be
based solely on economic aspects;
substItutIon
– In light of most medical public positions and based
on the opinion of most Portuguese rheumatologists,
automatic substitution should be currently consi -
dered unacceptable;
– If biosimilars have the same INN as the originator
molecule, prescription should be performed by
brand name;
InterchAngeAbIlIty
– Switching between the originator molecule and
biosimilars is not justifiable due to efficacy or safety
reasons (it will be only done in the context of an eco-
nomical advantage of the biosimilar) and must be
based on the attending physician decision and after
adequate patient information;
– When switching between biosimilars and the origi-
nator molecule, safety and efficacy assessments must
be performed and registered in Reuma.pt, following
a strategy analogue to the current national guide-
lines when initiating a new biologic drug; 
– Switching between the originator molecule and
biosimilars should occur after a minimum of 6
months use in order to allow for adequate efficacy,
safety and immunogenicity assessment;
extrAPolAtIon
– Extrapolation of indications approved for the origi-
nator drug to completely different diseases and age
groups that are not based on adequate pre-clinical,
safety and efficacy data (ideally phase I and phase
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tAble I. summAry of Included studIes
Position statements assorted according to the type of organization, country of origin of 
the organization and year of publication
Organisation Country of origin Year
Medical Societies/Colleges9 31%
American College of Rheumatology16 USA 2010
Colegio Mexicano de Reumatologia 17 Mexico 2012
American Academy of Dermatology 18 USA 2012
European Crohn’s and Colitis Organization19 Europe 2013
Sociedad Española de Patología Digestiva/ Sociedad Española de Farmacología 20 Spain 2013
Austrian Society of Hematology and Oncology 21 Austria 2008
Italian Society of Hematology22 Italy 2011
International Union of Angiology 23 International 2012
Société Française de Néphrologie/ Société Francophone de Dyalise 24 France 2009
Non-profit Non-governmental Organizations4 13.8%
National Psoriasis Foundation25 USA 2013
National Comprehensive Cancer Network26 USA 2011
National Haemophilia Foundation 27 USA 2009
Diabetes UK28 UK 2013
Pharmaceutical Organizations8 27.6%
European Biopharmaceutical Enterprises/ European Federation of Europe 2007
Pharmaceutical Industries and Associations 29
Biotechnology Industry Organization Deutschland30 Germany 2012
International Federation of Pharmaceutical Manufacturers and Associations31 International 2011
Organisation of Pharmaceutical Producers of India32 India 2012
Belgian Biotechnology Industry Organization33 Belgium 2013
Generic Pharmaceutical Association 34 USA 2013
Association of the British Pharmaceutical Industry35 UK 2013
Apifarma36 Portugal 2013
Governmental departments4 13.8%
Department of Health’s Ministerial Industry Strategy Group37 UK 2009
Agenzia Italiana del Farmaco38 Italy 2013
Scottish Medicines Consortium39 UK 2011
Health Canada40 Canada 2010
Pharmaceutical Manufacturers4 13.8%
Merck Sharp & Dohme41 USA 2010
Eli Lilly and Company42 USA 2010
F. Hoffmann-La Roche AG43 Switzerland 2010
Brystol Meyers Squibb44 UA 2013 
III trials) should not be performed;
ImmunogenIcIty
– Immunogenicity evaluation should be performed when
clinically relevant and available. As laboratorial me thods
of assessing immunogenicity are not routinely available
in clinical practice, immunogenicity must be inferred
from the adverse events and secondary loss of efficacy
data reported in the Reuma.pt register and this infor-
mation should be reported to health authorities;
Adverse events
– In face of the Portuguese law number 242/2002
(November 5 2002), the regulatory authorities, the
marketing authorization holder (former product li-
cense holder) and the healthcare professionals must
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tAble II. summAry of the PosItIon stAtements found
Position statements assorted by modality of use. the name and number of organizations that 
support the position are stated in the columns on the right-hand side. Although we performed a 
comprehensive search, for the sake of intelligibility, only the most relevant positions are 
displayed
Use Position statements Organizations that support the position Total, n (%)
Drug selection Therapeutic choice must primarily Apifarma 1 (3.4)
be dictated by patient safety concerns
The less expensive drug is a reasonable Agenzia Italiana del Farmaco 1 (3.4)
first therapeutic choice in naïve patients
Substitution Automatic substitution is unacceptable Apifarma
Austrian Society of Hematology and Oncology
Brystol-Meyers-Squibb
Colegio Mexicano de Reumatología
Eli Lilly and Company
F. Hoffmann- La Roche AG
Health Canada
Italian Society of Hematology, Italian Society 13 (44.8)
of Experimental Hematology, and Italian Group 
for Bone Marrow Transplantation
National Psoriasis Foundation
Scottish Medicines Consortium
Sociedad Española de Patología Digestiva/ 
/Sociedad Española de Farmacología 
Société Française de Néphrologie 
When biosimilars have the same INN, Apifarma
prescription must be performed by Association of the British Pharmaceutical Industry
brand name Belgian Biotechnology Industry Organization/ 
/Essenscia
Brystol-Meyers-Squibb
Diabetes UK
Generic Pharmaceutical Association
Health Canada
Italian Society of Hematology, Italian Society 12 (41.4)
of Experimental Hematology, and Italian Group 
for Bone Marrow Transplantation
Lilly
Scottish Medicines Consortium
Sociedad Española de Patología Digestiva/ 
/Sociedad Española de Farmacología
Société Française de Néphrologie, Société 
Francophone de Dyalise
Interchangeability Switching between biosimilars and Agenzia Italiana del Farmaco
the original product must be performed American Academy of Dermatology
only upon consent of the attending American College of Rheumatology
physician Apifarma
Association of the British Pharmaceutical Industry
Biotechnology Industry Organization Deutschland
continues on the next page
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tAble II. contInuAtIon
Use Position statements Organizations that support the position Total, n (%)
Brystol Meyers Squibb
Colegio Mexicano de Reumatología
Department of Health’s Ministerial Industry 
Strategy Group
Eli Lilly & company
European Biopharmaceutical Enterprises/ 
/European Federation of Pharmaceutical 
Industries and Associations
European Crohn’s and Colitis Organization 18 (62.1)
Merck
National Haemofilia Foundation
National Psoriasis Foundation
Organisation of Pharmaceutical Producers of India 
Sociedad Española de Patología Digestiva, 
Sociedad Española de Farmacología
Société Française de Néphrologie, 
Société Francophone de Dyalise
Switching requires informed consent Association of the British Pharmaceutical Industry
of the patient European Crohn’s and Colitis Organization
4 (13.8)
National Haemofilia Foundation
National Psoriasis Foundation
Extrapolation of Automatic extrapolation of safety and American College of Rheumatology
approval (to other efficacy data from the original drug Apifarma
indications of the should not be performed Biotechnology Industry Organization Deutschland
5 (17.2)
originator drug) European Crohn’s and Colitis Organization
Sociedad Española de Patología Digestiva/ 
/Sociedad Española de Farmacología
Extrapolation must be decided on a Association of the British Pharmaceutical Industry
case-by-case basis Austrian Society of Hematology and Oncology
4 (13.8)
Health Canada
Société Française de Néphrologie
The approval of the biosimilar drug Agenzia Italiana del Farmaco
automatically extends to all the Italian Society of Hematology, Italian Society of 
indications of the originator drug Experimental Hematology, and Italian Group for 3 (10.3)
Bone Marrow Transplantation
Scottish Medicines Consortium
Immunogenicity Immunogenicity must be adequately Diabetes UK
assessed Health Canada
International Federation of Pharmaceutical 
Manufacturers and Associations
Italian Society of Hematology, Italian Society 
of Experimental Hematology, and Italian Group 8 (27.6)
for Bone Marrow Transplantation
Merck
National Haemofilia Foundation
Organisation of Pharmaceutical Producers of India
Société Française de Néphrologie
continues on the next page
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tAble II. contInuAtIon
Use Position statements Organizations that support the position Total, n (%)
Adverse events Robust pharmacovigilance strategies American College of Rheumatology
must be assured Apifarma
Austrian Society of Hematology and Oncology
Belgian Biotechnology Industry Organization/
/Essenscia
Biotechnology Industry Organization Deutschland
Colegio Mexicano de Reumatología
Diabetes UK
Health Canada
International Federation of Pharmaceutical 
Manufacturers and Associations
17 (58.6)
International Union of Angiology
Italian Society of Hematology, Italian Society of 
Experimental Hematology, and Italian Group 
for Bone Marrow Transplantation
Lilly
Merck
Organisation of Pharmaceutical Producers of India
Scottish Medicines Consortium
Sociedad Española de Patología Digestiva/ 
/Sociedad Española de Farmacología
Société Française de Néphrologie
Patient registries and clinical databases American College of Rheumatology 1 (3.4)
are important sources of data 
concerning rare adverse events 
assure rigorous pharmacovigilance mechanisms;
– The brand name, batch number and date of admi -
nistration must be registered in the Reuma.pt
database upon every biosimilar drug administration; 
– Biosimilar-related adverse events registered in
Reuma.pt must be periodically monitored through
a formal evaluation.
glossAry
bIosImIlAr Products
Biological products that demonstrated its equivalence
to an already approved reference product with regard
to quality, safety, and efficacy
reference Product
A medicinal product that was approved on the basis of
a full data package (registration file). Reference pro -
ducts are used as the comparators in head-to-head
studies to show similarity in terms of quality, non-clini -
cal and clinical studies of biosimilar products.
orIgInAtor Product
A medicine that is the first to be approved by the na-
tional regulatory authorities on the basis of a full re -
gistration dossier. The originator product is usually
used as a reference product as it tends to be the pro duct
with publicly available safety information and long
market experience.
comPArAbIlIty
The scientific evaluation of a comparison of a biosimi -
lar product and a reference product to determine
absen ce of any detectable differences at the level of qua -
lity, non-clinical and clinical studies.
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clInIcAl equIvAlence
Clinical equivalence is granted when the evaluation ba -
sed on major clinical parameters is equivalent and when
any observed differences are clinically non-relevant.
ImmunogenIcIty
The ability of a substance to trigger an immune respon -
se or reaction (e.g., development of specific antibodies,
T cell response, allergic or anaphylactic reaction).
InterchAngeAbIlIty
This term means that the biosimilar product produces
the same clinical result as the reference product in any
given patient and, for a product administered more
than once, the safety and efficacy is not compromised
by alternating or switching between the reference pro -
duct and the biosimilar. An interchangeable biosimilar
has the potential to be used under the concept of au-
tomatic substitution. 
AutomAtIc substItutIon 
This is the legal authority for a pharmacy filling a pres -
cription to switch the innovator product to the biosimi -
lar without physician approval. This is not regulated
by EMA and was left to member states decision. 
extrAPolAtIon
Biosimilar products can be recognized for indications
of reference products without performing clinical stu -
dies for all the clinical indications that reference pro -
ducts are approved for, supposing the equivalence with
reference products by extrapolation of indications of
reference products. If equivalence on efficacy and safe-
ty of the biosimilar and the reference product have been
demonstrated in a particular indication, extrapolation
of these data to other indications of the reference pro -
duct may be possible if:
– A sensitive test model has been used, which is able
to detect potential differences between the biosimi-
lar and the reference product and
– The mechanism of action and/or involved recep-
tor(s) is the same
– Safety and immunogenicity have been sufficiently
characterized
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